Study finds drug-eluting stents exhibit some benefits over bare-metal stents in patients over 80, though both demonstrat

October 26, 2012

Rarely tested in patients over the age of 80, a study found that drug-eluting stents exhibited some benefits over bare-metal stents, though both types of stents demonstrated a clinical benefit. Results of the XIMA trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

Patients over the age of 80 are often excluded from randomized clinical trials, but this age group represents an increasing proportion of the daily revascularization workload, and in fact the fastest growing segment of the population. Octogenarians are more likely to present with complex coronary disease, anatomically expectant of drug- eluting stenting (DES). However, these same patients are at higher risk of bleeding complications from prolonged dual (DAPT).

XIMA is an international, multicenter, to examine the safety and efficacy outcomes among with either a bare-metal stent (BMS) or drug-eluting (DES) for complex coronary disease in the context of stable angina or an acute coronary syndrome. were excluded.

The trial enrolled 800 patients aged 80 or above who underwent angiography for stable angina or following an . If the coronary narrowing was deemed suitable for stenting and the lesion was either ≥15mm long and/or ≤3mm diameter, the patient was randomized to receive either BMS or DES. As long as stent deployment was considered feasible, there were no anatomical exclusions to the trial, which could include chronic total occlusions, bifurcations, severe calcification and left main stem lesions.

The primary endpoint of major adverse cardiac events (MACE) occurred in 18.7 percent of the BMS patients and 14.5 percent of the DES patients (p=0.092). Target vessel revascularization was 7 percent in the BMS group and 2 percent in the DES group (p=0.0009). Heart attack occurred in 8.7 percent of the BMS patients and 4.3 percent of the DES patients (p=0.01). There was no difference in mortality between the two groups at one year (7.2 percent vs. 8.5 percent, p=0.5) and no difference in the rates of major bleeding (1.7 percent vs. 2.3 percent, p=0.61).

"Results of the XIMA trial indicate that in patients over the age of 80, bare-metal and drug-eluting stents both offer good clinical results. Overall, patients who received drug-eluting stents experienced less major adverse cardiac events," said lead investigator Adam J. de Belder, MD. Dr. de Belder is Director of the Cardiac Catheter Laboratories at Brighton and Sussex University Hospitals in the United Kingdom.

"There were no differences in mortality between the two groups at one year and no difference in the rates of major bleeding, despite different dual antiplatelet therapy regimes. However there were significantly lower rates of target vessel revascularisation and myocardial infarction among DES-treated patients," said Dr. de Belder.

Explore further: Results of the DEB-AMI Trial reported at TCT 2011

Related Stories

Results of the DEB-AMI Trial reported at TCT 2011

November 10, 2011
A clinical trial that compared the use of drug-eluting balloons (DEB) and bare metal stents (BMS) to both bare metal stents alone and drug-eluting stents (DES) found that the drug-eluting balloon group did not meet the primary ...

Drug eluting stents used less often in women than men

August 27, 2012
Drug eluting stents (DES) are used less often in women treated with percutaneous coronary intervention (PCI) for coronary artery disease than men treated with PCI for the same condition, according to research presented today, ...

Results of the TWENTE trial reported at TCT 2011

November 11, 2011
The TWENTE clinical trial, which compared two second generation drug-eluting stents – zotarolimus and everolimus-eluting stents – established non-inferiority between the two stents as measured by the primary endpoint: ...

Drug-Eluting stents offer no advantage for A-Fib patients

June 22, 2012
(HealthDay) -- Drug-eluting stents (DESs) do not seem to offer advantages over bare-metal stents (BMSs) for patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI) with stent implantation, ...

Mesh-covered stent helps restoration of blood flow in heart attack patients undergoing PCI

October 24, 2012
A clinical trial found that the use of a next generation, micronet, mesh-covered stent demonstrated improved restoration of blood flow to heart tissue, compared to the use of either bare-metal or drug-eluting stents in heart ...

Second generation drug-eluting stents are safe and effective in treatment of left main coronary artery disease

October 24, 2012
A study found that second-generation drug-eluting stents are safe and effective in the treatment of left main coronary artery lesions. Results of the ISAR-LEFT MAIN 2 trial were presented at the 24th annual Transcatheter ...

Recommended for you

Hormone therapy in the menopause transition did not increase stroke risk

November 24, 2017
Postmenopausal hormone therapy is not associated with increased risk of stroke, provided that it is started early, according to a report from Karolinska Institutet published in the journal PLOS Medicine.

Low-salt and heart-healthy dash diet as effective as drugs for some adults with high blood pressure

November 22, 2017
A study of more than 400 adults with prehypertension, or stage 1 high blood pressure, found that combining a low-salt diet with the heart-healthy DASH diet substantially lowers systolic blood pressure—the top number in ...

Stroke patients may have more time to get treatment, study finds

November 22, 2017
Patients and doctors long have relied on a simple rule of thumb for seeking care after an ischemic stroke: "Time is brain."

Cases of heart failure continue to rise; poorest people worst affected

November 22, 2017
The number of people being diagnosed with heart failure in the UK continues to rise as a result of demographic changes common to many developed countries, new research by The George Institute for Global Health at the University ...

Some cancer therapies may provide a new way to treat high blood pressure

November 20, 2017
Drugs designed to halt cancer growth may offer a new way to control high blood pressure (hypertension), say Georgetown University Medical Center investigators. The finding could offer a real advance in hypertension treatment ...

Could this protein protect people against coronary artery disease?

November 17, 2017
The buildup of plaque in the heart's arteries is an unfortunate part of aging. But by studying the genetic makeup of people who maintain clear arteries into old age, researchers led by UNC's Jonathan Schisler, PhD, have identified ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.